Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02610764
Other study ID # ESO-CTC (Pilot)
Secondary ID
Status Completed
Phase N/A
First received November 15, 2015
Last updated April 12, 2017
Start date November 2015
Est. completion date December 2016

Study information

Verified date April 2017
Source University Hospital Freiburg
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate the feasibility of evaluation of prevalence and clinical significance and relevance of circulating tumor cells (CTC) in the blood of patients with resectable adenocarcinoma of the esophagus (EAC) treated with multimodal therapy in a pilot study. The primary hypothesis is that the number of CTC correlates with tumor burden and response to treatment. One established and one experimental CTC detection platform will be investigated. Investigators will evaluate the prevalence and enumeration of CTC before neoadjuvant treatment (time point 1), after neoadjuvant treatment & before operation (time point 2) and after the operation (time point 3). Results will be compared with healthy controls (one time point) and correlated with conventional response to treatment evaluation. The persistent presence of CTC could be a marker for worse response to treatment and predict early recurrence.


Description:

Little is known of the prevalence and clinical relevance of CTC in EAC, with the available data arising from heterogeneous patient populations using varied detection methods; but they are promising tools to improve staging and prediction of treatment response to perioperative and operative therapy.

The limited reports on resectable EAC use the epithelial-antibody dependent CellSearch method for CTC isolation and report a CTC-positivity rate of only 15-18% in non-pre-treated patients but with clinical relevance. It is thus needed to evaluate the relevance of CTC in the context of multimodal treatment courses.

This pilot study will investigate the CTC in the blood of patients with resectable EAC treated with multimodal therapy. Data on prevalence and enumeration of CTC will be generated. Two CTC isolation methods will be investigated, the established and expensive surface-antibody-dependent CellSearch method, and the antibody-independent and less expensive isolation by size (ISET; ScreenCell) method. The ISET method will additionally be investigated in healthy controls to get data on specificity.

The study can accomplish several goals through the use of two CTC detection platforms: 1) to determine the prevalence and number of CTC in resectable EAC under multimodal treatment, and 2) to investigate the potential role of CTC in predicting response to treatment and prognosis before neoadjuvant treatment, after neoadjuvant treatment and before operation as well as after the operation.

The primary hypothesis is that the enumeration of the CTC correlates with tumor burden and will reflect the response to treatment. To date the response to treatment is assessed with a combination of CT-morphologic, endoscopic, clinical (dysphagia) and finally histology. This assessment is used as control.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically verified adenocarcinoma of the esophagus According to the UICC definition (TNM7),

- pre-treatment stage cT1N+, M0 or cT2-4aN0/N+, M0 ,

- Age=18 years,

- scheduled for a multimodal therapeutic concept.

Exclusion Criteria:

- Tumors of squamous, adenosquamous or other non-adenocarcinoma histology, patients with advanced inoperable or metastatic esophageal adenocarcinoma.

- Esophageal adenocarcinoma cT1N0 and cT4b,

- Gastric carcinoma.

- Prior chemotherapy for gastrointestinal cancer. Clinically not eligible for surgery

Study Design


Intervention

Procedure:
Blood Test for CTC evaluation


Locations

Country Name City State
Germany University of Freiburg - Medical Center Freiburg Baden-Würtemberg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Freiburg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Overall survival The overall survival will be correlated with the number of CTC at the different timepoints. 2 years after recruitment of last patient
Other Progression free survival The progression free survival will be correlated with the number of CTC at the different time points. 2 years after recruitment of last patient
Primary Change of numbers of CTCs in patients with resectable EAC at diagnosis, after neoadjuvant treatment and after surgery. 1 year
Secondary Number of patients with detectable CTCs at diagnosis, after neoadjuvant treatment and after surgery. Number of patients with detectable CTCs isolated with the ISET device compared to the CellSearch method. 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04159974 - RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus Phase 2
Completed NCT03015389 - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Terminated NCT04642690 - Nitrates and IL-8 in Barrett's Esophagus
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Phase 2
Recruiting NCT04430738 - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Phase 1/Phase 2
Recruiting NCT04114136 - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Phase 2
Terminated NCT03223662 - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy Phase 2
Recruiting NCT05530343 - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance N/A
Active, not recruiting NCT03539822 - Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies Phase 1/Phase 2
Recruiting NCT05902988 - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Phase 1/Phase 2
Completed NCT01970306 - Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material Phase 2
Recruiting NCT06071845 - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples N/A
Active, not recruiting NCT02872116 - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Phase 3
Terminated NCT04089904 - Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma Phase 2
Recruiting NCT05177133 - Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) Phase 2
Recruiting NCT02962063 - Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer Phase 1/Phase 2
Recruiting NCT02606396 - Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer N/A
Terminated NCT00430027 - Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma N/A
Recruiting NCT05642338 - A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study